MA-2029

• Description :

  MA-2029 is a selective, orally active, and competitive motilin receptor antagonist (IC50=4.9 nM) . MA-2029 is selective for the motilin receptor over various other receptors and ion channels. MA-2029 may be useful for gastrointestinal disorders associated with disturbed gastrointestinal motility[1].

• UNSPSC :

  12352005

• Target :

  Motilin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/ma-2029.html

• Purity :

  98.94

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  FC(C=C1)=CC=C1C[C@H](NC)C(N(C)[C@@H](C(C)C)C(N[C@H](C(NCC)=O)CC2=CC(C(C)(C)C)=C(O)C=C2)=O)=O

• Molecular Formula :

  C31H45FN4O4

• Molecular Weight :

  556.71

• References & Citations :

  [1]Sudo H, et al. Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits. Eur J Pharmacol. 2008 Mar 10;581 (3) :296-305.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [287206-61-5]